NCT05505825 - A Study of AK104 in Combination With Chiauranib in Patients With Extensive Stage Small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 26, 2022

Primary Completion Date

July 19, 2024

Study Completion Date

July 31, 2024

Conditions

SCLC,Extensive Stage

Interventions

DRUG

AK104 IV infusion；Chiauranib oral

AK104 IV infusion once every 3 weeks；Chiauranib once a day oral

Trial Locations (7)

Jilin Province Cancer Hospital, Changchun

Westmead Hospital, Westmead

Icon Cancer Centre, South Brisbane

Princess Alexandra Hospital, Woolloongabba

Flinders Medical Centre, Bedford Park

Peninsula & South Eastern Haematology and Oncology Group, Frankston

Sunshine Hospital, St Albans